Cargando…

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease

Alzheimer’s disease, which is characterized by gradual cognitive decline associated with deterioration of daily living activities and behavioral disturbances throughout the course of the disease, is estimated to affect 27 million people around the world. It is expected that the illness will affect a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novakovic, Dijana, Feligioni, Marco, Scaccianoce, Sergio, Caruso, Alessandra, Piccinin, Sonia, Schepisi, Chiara, Errico, Francesco, Mercuri, Nicola B, Nicoletti, Ferdinando, Nisticò, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832388/ https://www.ncbi.nlm.nih.gov/pubmed/24255592 http://dx.doi.org/10.2147/DDDT.S53401

Ejemplares similares

Risk Factors for Alzheimer’s Disease: Focus on Stress
por: Caruso, Alessandra, et al.
Publicado: (2019)

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]
Publicado: (2014)

Inflammation Subverts Hippocampal Synaptic Plasticity in Experimental Multiple Sclerosis
por: Nisticò, Robert, et al.
Publicado: (2013)

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
por: Ostrowitzki, Susanne, et al.
Publicado: (2017)

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
por: Ostrowitzki, Susanne, et al.
Publicado: (2018)

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
por: Bateman, Randall J., et al.
Publicado: (2022)

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
por: Klein, Gregory, et al.
Publicado: (2019)

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
por: Söderberg, Linda, et al.
Publicado: (2022)

Corticotropin-Releasing Hormone: Biology and Therapeutic Opportunities
por: Caruso, Alessandra, et al.
Publicado: (2022)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease
por: Retout, Sylvie, et al.
Publicado: (2022)

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
por: Joseph‐Mathurin, Nelly, et al.
Publicado: (2022)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2022)

In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model
por: Aldea, Roxana, et al.
Publicado: (2022)

Targeting mGlu5 Metabotropic Glutamate Receptors in the Treatment of Cognitive Dysfunction in a Mouse Model of Phenylketonuria
por: Nardecchia, Francesca, et al.
Publicado: (2018)

Induction of the Wnt Antagonist Dickkopf-1 Is Involved in Stress-Induced Hippocampal Damage
por: Matrisciano, Francesco, et al.
Publicado: (2011)

Antidepressant activity of fingolimod in mice
por: di Nuzzo, Luigi, et al.
Publicado: (2015)

Targeting Synaptic Plasticity in Experimental Models of Alzheimer’s Disease
por: Mango, Dalila, et al.
Publicado: (2019)

Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia
por: Fazio, Francesco, et al.
Publicado: (2015)

Age-related changes of protein SUMOylation balance in the AβPP Tg2576 mouse model of Alzheimer's disease
por: Nisticò, Robert, et al.
Publicado: (2014)

Morphine Withdrawal Modifies Prion Protein Expression in Rat Hippocampus
por: Mattei, Vincenzo, et al.
Publicado: (2017)

Free D-aspartate regulates neuronal dendritic morphology, synaptic plasticity, gray matter volume and brain activity in mammals
por: Errico, F, et al.
Publicado: (2014)

NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer's disease
por: Triaca, Viviana, et al.
Publicado: (2016)

Rhes influences striatal cAMP/PKA-dependent signaling and synaptic plasticity in a gender-sensitive fashion
por: Ghiglieri, Veronica, et al.
Publicado: (2015)

Physical Exercise and Alzheimer’s Disease: Effects on Pathophysiological Molecular Pathways of the Disease
por: López-Ortiz, Susana, et al.
Publicado: (2021)

Biological Mechanism-based Neurology and Psychiatry: A BACE1/2 and Downstream Pathway Model
por: Hampel, Harald, et al.
Publicado: (2023)

Involvement of Bradykinin Receptor 2 in Nerve Growth Factor Neuroprotective Activity
por: Petrella, Carla, et al.
Publicado: (2020)

Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer’s disease course
por: Liguori, Claudio, et al.
Publicado: (2020)

Correction to: Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer’s disease course
por: Liguori, Claudio, et al.
Publicado: (2020)

Recovery of hippocampal functions and modulation of muscarinic response by electroacupuncture in young diabetic rats
por: Soligo, Marzia, et al.
Publicado: (2017)

Functional Correlates of Microglial and Astrocytic Activity in Symptomatic Sporadic Alzheimer’s Disease: A CSF/(18)F-FDG-PET Study
por: Bonomi, Chiara Giuseppina, et al.
Publicado: (2023)

Computational Analysis of Pathogenetic Pathways in Alzheimer’s Disease and Prediction of Potential Therapeutic Drugs
por: Petralia, Maria Cristina, et al.
Publicado: (2022)

Acid-sensing ion channel 1a: a novel target in Alzheimer’s disease?
por: Mango, Dalila, et al.
Publicado: (2022)

A Split-Wedge Anchorage for CFRP Cables: Numerical Model vs. Experimental Results
por: Damiani, Marco, et al.
Publicado: (2022)

Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimer’s Disease Patients and In Silico Prediction of Potential Repurposable Drugs
por: Fagone, Paolo, et al.
Publicado: (2022)

Presynaptic c-Jun N-terminal Kinase 2 regulates NMDA receptor-dependent glutamate release
por: Nisticò, Robert, et al.
Publicado: (2015)

Cognitive fluctuations in connection to dysgraphia: a comparison of Alzheimer’s disease with dementia Lewy bodies
por: Onofri, Emanuela, et al.
Publicado: (2015)

Targeting Microglia-Synapse Interactions in Alzheimer’s Disease
por: Piccioni, Gaia, et al.
Publicado: (2021)

Increased Heat Pain Tolerance but Hyperalgesia to Tonic Inflammatory Pain in the CRND8 Mouse Model of Alzheimer’s Disease
por: Merlo, Sara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6hllijfe4j8i576bg21gtfk4al